Management of nonmelanoma skin cancer in 2007

被引:190
作者
Neville, Julie A.
Welch, Erin
Leffell, David J.
机构
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Univ Texas, SW Med Ctr, Dallas, TX USA
来源
NATURE CLINICAL PRACTICE ONCOLOGY | 2007年 / 4卷 / 08期
关键词
management; Mohs micrographic surgery (MMS); nonmelanoma skin cancer (NMSC); review;
D O I
10.1038/ncponc0883
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
As the incidence of nonmelanoma skin cancer (NMSC) increases, so does the number of modalities used to treat this condition. Surgery is the most frequent approach used to treat NMSC, and clinicians usually perform Mohs micrographic surgery, conventional excision, electrodesiccation and curettage or cryosurgery. The 'gold standard' for treatment continues to be Mohs micrographic surgery, but owing to the time and expense involved with this procedure, it is indicated only in patients with aggressive tumors or those where disfigurement or functional impairment is a risk. Although radiation therapy is effective, its use is limited because of the side effects induced; radiation therapy can be used in certain patients who are not surgical candidates. Newer noninvasive options for NMSC include topical chemotherapeutics, biological-immune-response modifiers, retinoids, and photodynamic therapy, which can be used particularly in patients with superficial tumors. Treatments should be tailored to tumor type, location, size, and histological pattern, and although surgical methods remain the most frequently used, newer noninvasive treatments can be used in select tumors and may reduce morbidity.
引用
收藏
页码:462 / 469
页数:8
相关论文
共 47 条
[1]   THE MEANING OF SURGICAL MARGINS [J].
ABIDE, JM ;
NAHAI, F ;
BENNETT, RG .
PLASTIC AND RECONSTRUCTIVE SURGERY, 1984, 73 (03) :492-496
[2]   Nonmelanoma skin cancer [J].
Acartürk, TO ;
Edington, H .
CLINICS IN PLASTIC SURGERY, 2005, 32 (02) :237-+
[3]  
*AM CANC SOC, 2006, WHAT NONMELANOMA SKI
[4]   Surgical management of cutaneous malignancies [J].
An, KP ;
Ratner, DE .
CLINICS IN DERMATOLOGY, 2001, 19 (03) :305-320
[5]   PREVENTION OF SKIN-CANCER AND REDUCTION OF KERATOTIC SKIN-LESIONS DURING ACITRETIN THERAPY IN RENAL-TRANSPLANT RECIPIENTS - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY [J].
BAVINCK, JNB ;
TIEBEN, LM ;
VANDERWOUDE, FJ ;
TEGZESS, AM ;
HERMANS, J ;
TERSCHEGGET, J ;
VERMEER, BJ .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1933-1938
[6]   Imiquimod: a new immune response modifier for the treatment of external genital warts and other diseases in dermatology [J].
Berman, B .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2002, 41 :7-11
[7]   Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream [J].
Beutner, KR ;
Geisse, JK ;
Helman, D ;
Fox, TL ;
Ginkel, A ;
Owens, ML .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 41 (06) :1002-1007
[8]   Superficial and nodular basal cell carcinomas treated with an immune response modifier:: a report of seven patients [J].
Bianchi, L ;
Costanzo, A ;
Carnpione, E ;
Nisticò, S ;
Chimenti, S .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2003, 28 :24-26
[9]   Medical therapies for non-melanoma skin cancer [J].
Chakrabarty, A ;
Geisse, JK .
CLINICS IN DERMATOLOGY, 2004, 22 (03) :183-188
[10]   Cost of nonmelanoma skin cancer treatment in the United States [J].
Chen, JG ;
Fleischer, AB ;
Smith, ED ;
Kancler, C ;
Goldman, ND ;
Williford, PM ;
Feldman, SR .
DERMATOLOGIC SURGERY, 2001, 27 (12) :1035-1038